Kinopharma

Site map

Viral infection program

We kinopharma aim to develop the ideal treatment for viral diseases.

What is Virus?

 Viruses are very small simple structures which consist of the protein shell and the nucleic acid (genetic material) inside. Viruses infect to other organisms (host) and craftily use the host’s amplifying mechanism to amplify themselves. Infected host cells die, and this leads to various diseases.  

The antiviral drugs that Kinopharma aims to develop

We are developing therapeutic drugs that target the host kinases, which are used by viruses when the host is infected. We can expect the following by targeting the host:

1)Broad antiviral activity


2)Theoretically no emergence of any resistant virus to the drugs.
3)Antiviral activity to the viruses that are resistant to existent drugs.


Current state of development

<Development of drugs against DNA virus>
1) We have succeeded in creating a candidate compound for the clinical studies that exhibit broad spectrum of antiviral activity against viruses including Herpes virus, Varicella-Zoster virus, Cytomegalovirus, Adenovirus, Papilloma virus.
2) Confirmed that the candidate compound shows effect in inhibiting the amplification of acycrovil-resistant simple Herpes Virus.
3) Confirmed that the candidate compound shows significant therapeutic effect to skin infection animal model.
4) Confirmed the effect on hepatitis type B virus.
5) Currently conducting phase 1/2 study for HPV verrucosis.
<Development of a RNA viral illness curative medicine >
1) We succeeded in acquiring lead compounds for Hepatitis C, Influenza, Dengue, and Yellow fever viruses.
2) Currently proceeding optimization od structure.

Bibliography

Tanaka T, Okuyama-Dobashi K, Murakami S, Chen W, Okamoto T, Ueda K, Hosoya T, Matsuura Y, Ryo A, Tanaka Y, Hagiwara M, Moriishi K. (2016) Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation.
Antiviral Res.doi: 10.1016/j.antiviral.2016.08.008.

Yamamoto M, Onogi H, Kii I, Yoshida S, Iida K, Sakai H, Abe M, Tsubota T, Ito N, Hosoya T, and Hagiwara M. (2014) CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses.
J Clin Invest. 124(8):3479-3488.

Kusano-Kitazume A, Sakamoto N, Okuno Y, Sekine-Osajima Y, Nakagawa M, Kakinuma S, Kiyohashi K, Nitta S, Murakawa M, Azuma S, Nishimura-Sakurai Y, Hagiwara M, Watanabe M. (2012) Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication.
Antimicrob Agents Chemother. 56(3):1315-23.

Anwar A, Hosoya T, Leong KM, Onogi H, Okuno Y, Hiramatsu T, Koyama H, Suzuki M, Hagiwara M, Garcia-Blanco MA. (2011) The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly.
PLoS One. 6(8):e23246.

Karakama, Y., Sakamoto, N., Itsui, Y., Nakagawa, M., Tasaka-Fujita, M., Nishimura-Sakurai, Y., Kakinuma, S., Oooka, M., Azuma, S., Tsuchiya, K., et al. (2010).
Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase.
Antimicrob Agents Chemother 54, 3179-3186.

Fukuhara T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y, Suzuki M, Yamamoto N, Herzenberg LA, Herzenberg LA, Hagiwara M. (2006) Utilization of host SR protein kinases and RNA-splicing machinery during viral replication.
Proc Natl Acad Sci U S A. Jul 25;103(30):11329-33.
  • About kinase
  • パイプライン
  • ウイルス性疾患治療薬
  • 中枢神経系疾患治療薬
  • Exploratory Research
  • 基盤技術
  • Collaboration

About usSite map